Dr Alwin Tan, MBBS, FRACS, EMBA (Melbourne Business School)

Senior Surgeon | Governance Leader | HealthTech Co-founder
Harvard Medical School — AI in Healthcare
Australian Institute of Company Directors — GAICD candidate
University of Oxford — Sustainable Enterprise

Institute for Systems Integrity (ISI)
Governance. Integrity. Systems.

Executive Summary

Healthcare governance failures rarely arise from poor intent.

They arise when decision systems operate with degraded clinical signal.

A common but under-recognised driver is functional clinical absence — where clinical representation exists, but the right clinician perspective is missing, muted, or structurally constrained.

When this occurs:

• Decisions remain technically sound
• Assumptions receive insufficient challenge
• Operational realities are underweighted
• Implementation friction increases
• Safety margins may narrow

This is not a behavioural issue.

It is a governance design failure.

The Wrong Question

Most boards ask:

“Do we have a clinician?”

This is the wrong question.

The governance-critical question is:

“Does the right clinician meaningfully influence decision quality?”

Because presence alone does not protect governance.

Only functional clinical signal does.

Defining the “Right Clinician” (Governance Context)

From a systems integrity perspective, the right clinician contributes:

• Contemporary operational insight
• Deep understanding of care delivery constraints
• Independence of judgement
• Willingness to challenge assumptions
• Capacity to introduce constructive tension

Clinical expertise without independence becomes advisory.

Clinical presence without challenge becomes symbolic.

Symbolic Representation and the Illusion of Assurance

A recurrent governance pattern:

A clinician is appointed based on:

• Familiarity with leadership
• Cultural alignment
• Perceived agreeability

The role evolves into:

✔ Legitimising presence
✖ Limited assumption challenge
✖ Reduced cognitive diversity
✖ Constrained dissent

This creates the illusion of clinical validation while weakening decision robustness.

Mechanism of Governance Blindness

When the right clinician signal is absent, governance relies on:

• Abstracted metrics
• Financial models
• Policy assumptions

without sufficient testing against frontline realities such as:

• Workflow constraints
• Throughput variability
• Training burden
• Interdependent resource effects
• Safety trade-offs

The decision is not incorrect.

It is under-informed.

Where This Risk Materialises

1️⃣ Technology Investment

Without appropriate clinical challenge:

• ROI assumptions are flattened
• Workflow disruption is underestimated
• Learning curves are ignored
• Downstream impacts are obscured

Result:

• Implementation underperformance
• Friction misattributed to resistance

2️⃣ Clinical Policy

Absent or weakened clinical input leads to:

• Oversimplified care models
• Distorted risk narratives
• Feasibility gaps

Result:

• Policy-practice misalignment
• Workarounds and inefficiency
• Increased system strain

3️⃣ Value-Based Care Decisions

When operational insight is diluted:

• Early intervention value is under-recognised
• Cost-risk assumptions become outdated

Governance Implications

Functional clinical absence degrades:

✔ Information fidelity
✔ Risk calibration
✔ Feasibility assessment
✔ Implementation stability

while preserving:

✔ Procedural compliance
✔ Surface-level consensus
✔ Decision comfort

This creates governance blindness — decisions made without sufficient visibility of real-world consequences.

The Governance Paradox

Boards optimise for:

• Alignment
• Stability
• Collegiality

Yet resilient systems depend on:

• Cognitive diversity
• Constructive tension
• Independent challenge

Especially from those closest to care delivery.

Structural Drivers of Functional Absence

Clinical disengagement is often structural:

• Procedural schedules limit participation
• Governance roles lack protected time
• Contribution is undervalued or symbolic
• Participation is not designed around clinical realities

This is not reluctance.

It is system design failure.

Designing Governance Against Blindness

1️⃣ Selection Integrity

Clinicians selected for:

✔ Currency
✔ Independence
✔ Operational credibility
✔ Willingness to challenge

2️⃣ Explicit Governance Role

Expectation that clinicians:

✔ Stress-test assumptions
✔ Surface constraints
✔ Challenge feasibility

3️⃣ Structural Enablement

• Protected governance time
• Distributed clinician participation
• Scheduling aligned to clinical realities

4️⃣ Diversity of Clinical Input

Avoid reliance on:

✖ A single “clinical voice”

Reframing Governance

Not:

“Do we have clinical representation?”

But:

“Does clinical expertise function as an active governance control?”

Conclusion

Healthcare systems do not fail because clinicians are absent.

They fail when the wrong clinical signal shapes decisions — or when the right signal is missing.

Because if the right clinician is not in the room,

governance does not stop.

It continues —
with weaker visibility,
reduced challenge,
and increased risk.

That is governance blindness.

References (Harvard Style)

Australian Commission on Safety and Quality in Health Care (ACSQHC) 2017, National Model Clinical Governance Framework, ACSQHC, Sydney.

Australian Institute of Company Directors (AICD) 2019, Good Governance Principles and Guidance for Not-for-Profit Organisations, 4th edn, AICD, Sydney.

Brown, A 2019, ‘Governing the quality and safety of healthcare: A conceptual framework’, Social Science & Medicine, vol. 238, 112–117.

Prenestini, A, Lega, F & Masella, C 2023, ‘Physician engagement in health care organizations: A systematic review’, BMC Health Services Research, vol. 23, no. 1.

Royal Australasian College of Surgeons (RACS) 2017, Clinical Governance Frameworks Report, RACS, Melbourne.

Safer Care Victoria 2017, Victorian Clinical Governance Framework, Victorian Government, Melbourne.

World Health Organization (WHO) 2014, Strengthening clinical governance for quality and safety, WHO, Geneva.

World Health Organization (WHO) 2021, Global Patient Safety Action Plan 2021–2030, WHO, Geneva.